Pembro/Carbo/Taxol in Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 22, 2017

Primary Completion Date

December 12, 2019

Study Completion Date

February 10, 2022

Conditions
Endometrial CancerEndometrial Adenocarcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg will be administered every 3 weeks for all subjects

DRUG

Paclitaxel

"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."

DRUG

Carboplatin

"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."

Trial Locations (6)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

52242

University of Iowa Hospitals and Clinics, Iowa City

55455

University of Minnesota, Minneapolis

60045

Northwestern Medicine Lake Forest Hospital, Lake Forest

60611

Northwestern University, Robert H. Lurie Cancer Center, Chicago

85206

Ironwood Cancer and Research Centers, Mesa

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Hoosier Cancer Research Network

OTHER

lead

Daniela Matei, MD

OTHER